MHRA-101226-PIP01-23

Key Facts

PIPS Key Facts
Active Substance
Active Substance:
  • Volrustomig
Invented Name
Volrustomig
PIP Number MHRA-101226-PIP01-23
Pharmaceutical form(s)
Pharmaceutical form(s):
  • Concentrate for solution for injection/infusion
Therapeutic area
Therapeutic area:
  • Oncology
Conditions / Indications
  • Treatment of cervical cancer
  • Treatment of renal cell carcinoma
  • Treatment of lung cancer
  • Treatment of mesothelioma
Route(s) of administration
Route(s) of administration:
  • Intravenous use
PIP applicant
Decision Type
Decision Type
W: decision granting a waiver in all age groups for the listed condition(s).
Compliance Check
Compliance Check
No
Compliance Check Decision Date
Compliance Check Procedure Number

Decision Document

PIPS Decision Documents
Decision Document Decision Document on a Paediatric Investigation Plan (PIP):Volrustomig.pdf
Published Date 24/06/2024